Communication Training for Cancer Patients, Their Caregivers, and Their Doctors
NCT ID: NCT04479605
Last Updated: 2025-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2020-07-15
2025-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The VOICE 2.0 intervention was developed by members of the study team to improve communication among oncologists, patients with cancer, and caregivers. Researchers have found that clear communication about the patient's disease can help with the planning of that patient's future care and improve the well-being of both the patient and his or her caregiver. The long-term goals of developing and testing VOICE 2.0 include improving the care and respecting the wishes of cancer patients, and helping those patients and their caregivers have an improved quality of life during their experience with cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VOICE: Values and Options in Cancer Care
NCT01485627
Values and Options in Cancer Care 2 (VOICE 2) A Randomized Pilot Study
NCT05352451
Improving Communication Between Cancer Patients & Oncologists
NCT02969031
Communication Training for Caregivers In Advanced Care Planning
NCT04171895
Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles
NCT00582192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with advanced cancer
Patient and caregiver coaching is facilitated by a booklet titled Our Cancer Care (Appendices E \& F) that includes a Question Prompt List (QPL) and resources for a Values Affirmation Exercise (Appendices G \& H). The QPL and Values Affirmation Exercises will be provided with a cover letter (Appendix I). The QPL consists of example questions to discuss with oncologists about diagnosis, prognosis, treatments, symptom management, transitions in care, self-care, family needs, and life goals. Patients and caregivers meet over video-conferencing with a study interventionist for one hour to review the QPL. The interventionist makes three follow-up phone calls to each dyad bi-weekly to evaluate use of the QPL.
No interventions assigned to this group
Caregivers
Caregivers will participate in three 45-minute sessions with the interventionist over the telephone or video-conferencing (per caregiver preference) approximately bi-weekly. These sessions take place while the patient and caregiver are completing the three follow-up dyadic sessions. Efforts will be made to schedule the caregiver support sessions during weeks that fall between dyadic coaching sessions to minimize intervention burden on caregivers (i.e., avoiding scheduling two sessions for the caregiver in the same week).
No interventions assigned to this group
Oncologists
The Oncologist training will be conducted online using Bridge, an internet-based platform designed to facilitate communication between instructors and learners. The training includes written information on and videos demonstrating target communication skills (Table 1) and knowledge acquisition checks. Five of the online modules are required and the remaining six modules are optional. The required modules are estimated to take oncologists approximately one hour to complete; the optional modules are estimated to take 90 minutes total (i.e., for all modules) to complete. Oncologists' logging history will be tracked in Bridge.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* As per self-report, medical oncologist providing care to patients with gastrointestinal, genitourinary, gynecologic, lung, or hematologic cancers at MSK
* As per self-report, not planning to leave MSK in the next six months
* As per self-report, willing to be audio-recorded for Post-Training Follow-Up Interview
PATIENTS:
* Per medical record and/or self-report, a patient of an oncologist participating in this study
* As per medical record and/or self-report, diagnosis of:
* a hematologic cancer with disease progression following second-line treatment that is not eligible for transplant; OR
* stage III or IV gastrointestinal, genitourinary, gynecologic, or lung cancer
* As per medical record and/or self-report, fluent in English
* As per medical record and/or self-report, age 18 or older
* As per self-report, has a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) who is willing and able to participate in the study
* As per self-report, residency in New York or ability to complete sessions in New York to ensure that provision of intervention is covered by the professional licenses of interventionists (i.e., social workers licensed in New York State)
* As per self-report, able to communicate over video-conference and phone for sessions
* As per self-report, willing to be audio-recorded for assessments and study sess
CAREGIVERS:
* As per patient report, is a primary informal caregiver ("a family member, partner, friend, or other individual involved with your health care issues, preferably someone who comes to physician appointments with you") for an MSK patient
* As per self-report, fluent in English
* As per self-report, age 18 or older
* As per self-report, ability to complete sessions in a state the interventionists are legally allowed to practice in (i.e., social workers licensed in New York or New Jersey State; states with shared license laws)
* As per self-report, able to communicate over video-conference and phone for sessions
* As per self-report, willing to be audio-recorded for assessments and study sessions \*\* Language verification: For both patients and caregivers, prior to enrollment, all will be asked the following two questions by an CRC to verify English fluency necessary for participation in the study:
1. How well do you speak English? (must respond "Very well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)
Exclusion Criteria
* Score \>4 on Short Portable Mental Status Questionnaire
* As per self-report, feels too weak or cognitively impaired to participate in the intervention and complete the assessments
* As per medical record or self-report, receiving hospice care at the time of enrollment
CAREGIVERS:
* Score \>4 on Short Portable Mental Status Questionnaire
* As per self-report, feels too weak or cognitively impaired to participate in the intervention and complete the assessments
* As per medical record or self-report, receiving hospice care at the time of enrollment
* As per patient or self-report, supports the patient in a professional role
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kelly Trevino, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-241
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.